NeueHealth price target raised to $8 from $7 at RBC Capital

RBC Capital raised the firm’s price target on NeueHealth to $8 from $7 and keeps a Sector Perform rating on the shares. The firm is updating its model as it sees the company’s liquidity improving folloing the sale of its California Medicare Advantage business, the analyst tells investors in a research note.